Summary by Futu AI
Knight Therapeutics Inc, a former 10% owner of 60 Degrees Pharmaceuticals, has engaged in a planned transaction on July 28, 2023. The transaction involved the acquisition of 45,560 shares of common stock at a price of $4.745 per share and the disposal of 2,162 shares of Series A Non-Voting Convertible Preferred Stock at no cost. Following these transactions, Knight Therapeutics Inc's indirect beneficial ownership, through Knight Therapeutics International S.A., will amount to 78,803 shares of 60 Degrees Pharmaceuticals.